Cardiome Enters Commercialization Agreement With Algorithm S.A.L. For BRINAVESS™ In Middle East And North Africa

Cardiome Enters Commercialization Agreement With Algorithm S.A.L. For 
BRINAVESS™ In Middle East And North Africa 
VANCOUVER, Oct. 21, 2013 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: 
COM) today announced that its subsidiary, Cardiome International AG, has 
entered into an agreement with Algorithm S.A.L., headquartered in Beirut, 
Lebanon, to sell and distribute BRINAVESS™ (vernakalant intravenous) 
exclusively in certain Middle Eastern and North African countries. Under the 
terms of the agreement, Algorithm has agreed to specific annual commercial 
goals for BRINAVESS. Financial details of the agreement have not been 
"We are pleased to have entered into this commercialization agreement with 
Algorithm, a highly respected company with an impressive track record in 
partnering with other pharma industry leaders," said Karim Lalji, Cardiome's 
Chief Commercial Officer. "We look forward to continuing the commercialization 
of BRINAVESS in approved markets and leveraging Algorithm's expertise in 
gaining approvals in new ones." 
"Algorithm is excited to be working with Cardiome to sell and distribute 
BRINAVESS," said Nabil Ghorayeb, Human Health Lead, at Algorithm. "Our company 
has a long and successful history in the cardiovascular market, and BRINAVESS 
is an excellent addition to our product portfolio that will offer our 
customers a treatment option for the rapid conversion of recent onset atrial 
The initial term of this commercial agreement begins November 1, 2013 for the 
duration of five years and is renewable on an annual basis, or longer, 
thereafter. Countries covered by the agreement where Algorithm will be able to 
commercialize BRINAVESS include: Algeria; Bahrain; Egypt; Iran; Jordan; 
Kingdom of Saudi Arabia; Kuwait; Lebanon; Libya; Morocco; Oman; Qatar; 
Tunisia; and United Arab Emirates. 
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the 
discovery, development and commercialization of new therapies that will 
improve the health of patients around the world. Cardiome has one marketed 
product, BRINAVESS(TM) (vernakalant IV), approved in Europe and other 
territories for the rapid conversion of recent onset atrial fibrillation to 
sinus rhythm in adults. 
Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock 
Exchange (COM). For more information, please visit our web site at 
About Algorithm S.A.L.
Algorithm, a Lebanon-based pharmaceutical manufacturer, is actively present in 
the Middle East and North Africa region and Cyprus. Algorithm is dedicated 
to offering quality products, either under license from reputable 
international companies or developed by the company's product development 
team. The portfolio consists of innovative products as well as differentiated 
generics, focusing mainly on the following therapeutic areas: Cardiometabolic 
Diseases, Neurology, Endocrinology, Onco-Hematology, Uro-Gynecology, and 
Dermatology. For more information, visit 
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements 
within the meaning of the Private Securities Litigation Reform Act of 1995 or 
forward-looking information under applicable Canadian securities legislation 
that may not be based on historical fact, including without limitation 
statements containing the words "believe", "may", "plan", "will", "estimate", 
"continue", "anticipate", "intend", "expect" and similar expressions. 
Forward- looking statements may involve, but are not limited to, comments with 
respect to our objectives and priorities for the remainder of 2013 and beyond, 
our strategies or future actions, our targets, expectations for our financial 
condition and the results of, or outlook for, our operations, research and 
development and product and drug development. Such forward-looking statements 
involve known and unknown risks, uncertainties and other factors that may 
cause the actual results, events or developments to be materially different 
from any future results, events or developments expressed or implied by such 
forward-looking statements. Many such known risks, uncertainties and other 
factors are taken into account as part of our assumptions underlying these 
forward-looking statements and include, among others, the following: general 
economic and business conditions in the United States, Canada, Europe, and the 
other regions in which we operate; market demand; technological changes that 
could impact our existing products or our ability to develop and commercialize 
future products; competition; existing governmental legislation and 
regulations and changes in, or the failure to comply with, governmental 
legislation and regulations; availability of financial reimbursement coverage 
from governmental and third-party payers for products and related treatments; 
adverse results or unexpected delays in pre-clinical and clinical product 
development processes; adverse findings related to the safety and/or efficacy 
of our products or products; decisions, and the timing of decisions, made by 
health regulatory agencies regarding approval of our technology and products; 
the requirement for substantial funding to expand commercialization 
activities; and any other factors that may affect our performance. In 
addition, our business is subject to certain operating risks that may cause 
any results expressed or implied by the forward-looking statements in this 
presentation to differ materially from our actual results. These operating 
risks include: our ability to attract and retain qualified personnel; our 
ability to successfully complete pre-clinical and clinical development of our 
products; changes in our business strategy or development plans; intellectual 
property matters, including the unenforceability or loss of patent protection 
resulting from third-party challenges to our patents; market acceptance of our 
technology and products; our ability to successfully manufacture, market and 
sell our products; the availability of capital to finance our activities; and 
any other factors described in detail in our filings with the Securities and 
Exchange Commission available at and the Canadian securities 
regulatory authorities at Given these risks, uncertainties and 
factors, you are cautioned not to place undue reliance on such forward-looking 
statements and information, which are qualified in their entirety by this 
cautionary statement. All forward-looking statements and information made 
herein are based on our current expectations and we undertake no obligation to 
revise or update such forward-looking statements and information to reflect 
subsequent events or circumstances, except as required by law.

SOURCE  Cardiome Pharma Corp. 
Cardiome Investor Relations (604) 676-6993 or Toll Free: 1-800-330-9928 
To view this news release in HTML formatting, please use the following URL: 
CO: Cardiome Pharma Corp.
ST: British Columbia
-0- Oct/21/2013 12:45 GMT
Press spacebar to pause and continue. Press esc to stop.